Trials / Unknown
UnknownNCT03777085
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2303 | 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks |
| DRUG | Rituximab | 375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks |
Timeline
- Start date
- 2019-01-10
- Primary completion
- 2020-12-30
- Completion
- 2020-12-30
- First posted
- 2018-12-17
- Last updated
- 2019-05-30
Locations
31 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03777085. Inclusion in this directory is not an endorsement.